Business Wire

Chinese Tourists Can Now Pay with Alipay at More Than 300,000 Merchants in Japan, Six Times More Than a Year Ago

Share

Alipay, the world’s leading payment and lifestyle platform operated by Ant Financial, has connected more than 300,000 Japanese merchants as of early 2019 with tourists from Chinese mainland paying through the Alipay app.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005435/en/

A pharmacy in Tokyo accepting Alipay.

A pharmacy in Tokyo accepting Alipay.

This was an increase of about 500 percent compared with the beginning of 2018, when 50,000 merchants in Japan accepted Alipay, amid a push by the Japanese government to drive greater adoption of mobile payments.1

Japan is one of the most popular destinations for holiday by Chinese tourists, according to statistics compiled by Alipay, which is also working with its e-wallet strategic partners in other Asian markets to bring more consumers to Japan in the near future. Alipay’s e-wallet partners include TrueMoney in Thailand, GCash in the Philippines, kakaopay in the Republic of Korea, and Paytm in India.

Over China’s the four-day long Labour Day holidays in early May, Japan was ranked fourth highest among all the overseas destinations in terms of total Alipay transaction volume. The country also posted one of the biggest increases in tourist spending, with average spending on Alipay per person rising 25% year-on-year. During the period, the most popular merchants for shoppers were convenience stores, airport shops, and department stores, according to Alipay statistics.

More tourists are expected to visit Japan in the coming years and Alipay is working to help local merchants cope with the influx through digital payments, while providing tourists with the mobile payment experience that they are familiar with back home. 2

For example, users of AlipayHK - the e-wallet for Hong Kong citizens jointly developed by Alipay and CKHH - can now use the e-wallets in the Daimaru Tenjin store in Fukuoka, with the service expected to expand to the whole of Japan in the near future.

“Alipay has been providing technology support to our nine e-wallet partners to enhance their cross-border payment capabilities, and hopefully to bring more Asian customers to Japan and contribute to revitalizing the local economy,” said Eric Jing, Chairman and CEO of Ant Financial.

“We are dedicated to supporting small and micro businesses around the world through our technology. Digital wallets like Alipay are not only convenient payment tools, but also smart marketing platforms to connect merchants and their potential customers before, during and after their visits to Japan,” Eric added.

Nearly 60 per cent of overseas bricks-and-mortar merchants that adopted Alipay saw a subsequent growth in both foot traffic and revenue, according to the report 2018 Trends for Mobile Payment in Chinese Outbound Tourism by Nielsen. A separate report, Outbound Chinese Tourism andConsumption Trend: 2017 Survey, found that over 90% of Chinese tourists would use mobile payment while traveling overseas if they were given the option.

China is the largest tourism market for Japan, accounting for 27% percent of the 31 million tourists who visited the country in 2018. Tourists from Asia as a whole reached 26 million last year, accounting for more than 86% of Japan’s total visitor number.3

About Alipay

Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay currently serves over 1 billion users with its local e-wallets partners. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites. Alipay currently supports 27 currencies.

1 https://www.japantimes.co.jp/news/2018/12/03/reference/japan-grudgingly-heads-toward-cashless-society/#.XNpAf9MzbOQ

2 https://www.telegraph.co.uk/travel/destinations/asia/japan/articles/japan-fastest-growing-travel-destination/

3 https://www.jnto.go.jp/jpn/statistics/visitor_trends/index.html

Contact information

Xinyun Yang
+86 13816896301
xinyun.yang@antfin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom